It has been reported that bevacizumab, an antivascular endothelial growth factor (VEGF) antibody, was effective in non‐small cell lung cancer (NSCLC) patients with MPE in two randomized studies in Japan.5, 6 However, there are no data to suggest that ramucirumab, an anti‐VEGF antibody that is used in the clinical setting, has the same effect. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.